Skip to main content

14.05.2024 | Nephrology – Original Paper

Effects of incremental peritoneal dialysis with low glucose-degradation product neutral pH solution on clinical outcomes

verfasst von: Hasan Haci Yeter, Murat Altunok, Erdem Cankaya, Saliha Yildirim, Serkan Akturk, Serkan Bakirdogen, Hadim Akoğlu, Mesudiye Bulut, Tuncay Sahutoglu, Arda Erdut, Mehmet Ozkahya, Yener Koc, Onur Tunca, Ekrem Kara, Müge Erek, Mehmet Polat, Tulin Akagun, Galip Guz

Erschienen in: International Urology and Nephrology

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Incremental peritoneal dialysis (IPD) could decrease unfavorable glucose exposure results and preserve (RKF). However, there is no standardization of dialysis prescriptions for patients undergoing IPD. We designed a prospective observational multi-center study with a standardized IPD prescription to evaluate the effect of IPD on RKF, metabolic alterations, blood pressure control, and adverse outcomes.

Methods

All patients used low GDP product (GDP) neutral pH solutions in both the incremental continuous ambulatory peritoneal dialysis (ICAPD) group and the retrospective standard PD (sPD) group. IPD patients started treatment with three daily exchanges five days a week. Control-group patients performed four changes per day, seven days a week.

Results

A total of 94 patients (47 IPD and 47 sPD) were included in this study. The small-solute clearance and mean blood pressures were similar between both groups during follow-up. The weekly mean glucose exposure was significantly higher in sPD group than IPD during the follow-up (p < 0.001). The patients with sPD required more phosphate-binding medications compared to the IPD group (p = 0.05). The rates of peritonitis, tunnel infection, and hospitalization frequencies were similar between groups. Patients in the sPD group experienced more episodes of hypervolemia compared to the IPD group (p = 0.007). The slope in RKF in the 6th month was significantly higher in the sPD group compared to the IPD group (65% vs. 95%, p = 0.001).

Conclusion

IPD could be a rational dialysis method and provide non-inferior dialysis adequacy compared to full-dose PD. This regimen may contribute to preserving RKF for a longer period.
Literatur
1.
Zurück zum Zitat Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR (1997) Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 8:965–971CrossRefPubMed Churchill DN, Thorpe KE, Vonesh EF, Keshaviah PR (1997) Lower probability of patient survival with continuous peritoneal dialysis in the United States compared with Canada. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 8:965–971CrossRefPubMed
2.
Zurück zum Zitat Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, Group MNCS (2002) Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307–1320CrossRefPubMed Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, Group MNCS (2002) Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307–1320CrossRefPubMed
3.
Zurück zum Zitat Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT (2003) The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41:1293–1302CrossRefPubMed Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT (2003) The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41:1293–1302CrossRefPubMed
4.
Zurück zum Zitat Fernandes A, Matias P, Branco P (2023) Incremental peritoneal dialysis—definition, prescription, and clinical outcomes. Kidney360 4:272–277CrossRefPubMed Fernandes A, Matias P, Branco P (2023) Incremental peritoneal dialysis—definition, prescription, and clinical outcomes. Kidney360 4:272–277CrossRefPubMed
5.
Zurück zum Zitat Golper T, Churchill D, Burkart J, Firanek C, Geary D, Gotch F, Moore L, Nolph K, Powe N, Singh H (1997) NKF DOQI clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 30:S67-136CrossRef Golper T, Churchill D, Burkart J, Firanek C, Geary D, Gotch F, Moore L, Nolph K, Powe N, Singh H (1997) NKF DOQI clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 30:S67-136CrossRef
6.
Zurück zum Zitat Dhoot A, Brown EA, Robinson B, Perl J (2023) Incremental peritoneal dialysis: incremental gains. SAGE Publications, London, pp 355–358 Dhoot A, Brown EA, Robinson B, Perl J (2023) Incremental peritoneal dialysis: incremental gains. SAGE Publications, London, pp 355–358
7.
Zurück zum Zitat Brown EA, Blake PG, Boudville N, Davies S, de Arteaga J, Dong J, Finkelstein F, Foo M, Hurst H, Johnson DW (2020) International society for peritoneal dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis. Perit Dial Int 40:244–253CrossRefPubMed Brown EA, Blake PG, Boudville N, Davies S, de Arteaga J, Dong J, Finkelstein F, Foo M, Hurst H, Johnson DW (2020) International society for peritoneal dialysis practice recommendations: prescribing high-quality goal-directed peritoneal dialysis. Perit Dial Int 40:244–253CrossRefPubMed
8.
Zurück zum Zitat Cheetham MS, Cho Y, Krishnasamy R, Jain AK, Boudville N, Johnson DW, Huang LL (2022) Incremental versus standard (full-dose) peritoneal dialysis. Kidney Int Rep 7:165–176CrossRefPubMed Cheetham MS, Cho Y, Krishnasamy R, Jain AK, Boudville N, Johnson DW, Huang LL (2022) Incremental versus standard (full-dose) peritoneal dialysis. Kidney Int Rep 7:165–176CrossRefPubMed
9.
Zurück zum Zitat Auguste BL, Bargman JM (2018) Incremental peritoneal dialysis: new ideas about an old approach. Semin Dial 31:445–448CrossRefPubMed Auguste BL, Bargman JM (2018) Incremental peritoneal dialysis: new ideas about an old approach. Semin Dial 31:445–448CrossRefPubMed
10.
Zurück zum Zitat Nolph KO, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP (1987) Peritoneal equilibration test. Perit Dial Int 7:138–148CrossRef Nolph KO, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP (1987) Peritoneal equilibration test. Perit Dial Int 7:138–148CrossRef
11.
Zurück zum Zitat Li PKT, Chow KM, Cho Y et al (2022) ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 42(2):110–153CrossRefPubMed Li PKT, Chow KM, Cho Y et al (2022) ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 42(2):110–153CrossRefPubMed
13.
Zurück zum Zitat Cheetham MS, Cho Y, Krishnasamy R, Milanzi E, Chow J, Hawley C, Moodie J-A, Jose MD, MacGinley R, Nguyen T (2023) Multicentre registry analysis of incremental peritoneal dialysis incidence and associations with patient outcomes. Perit Dial Int 43:383–394CrossRefPubMed Cheetham MS, Cho Y, Krishnasamy R, Milanzi E, Chow J, Hawley C, Moodie J-A, Jose MD, MacGinley R, Nguyen T (2023) Multicentre registry analysis of incremental peritoneal dialysis incidence and associations with patient outcomes. Perit Dial Int 43:383–394CrossRefPubMed
14.
Zurück zum Zitat Sandrini M, Vizzardi V, Valerio F, Ravera S, Manili L, Zubani R, Lucca BJ, Cancarini G (2016) Incremental peritoneal dialysis: a 10 year single-centre experience. J Nephrol 29:871–879CrossRefPubMedPubMedCentral Sandrini M, Vizzardi V, Valerio F, Ravera S, Manili L, Zubani R, Lucca BJ, Cancarini G (2016) Incremental peritoneal dialysis: a 10 year single-centre experience. J Nephrol 29:871–879CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Tomo T, Okabe E, Matsuyama K, Iwashita T, Yufu K, Nasu M (2005) The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model. J Artif Organs 8:125–129CrossRefPubMed Tomo T, Okabe E, Matsuyama K, Iwashita T, Yufu K, Nasu M (2005) The effect of peritoneal rest in combination therapy of peritoneal dialysis and hemodialysis: using the cultured human peritoneal mesothelial cell model. J Artif Organs 8:125–129CrossRefPubMed
16.
Zurück zum Zitat Ueda A, Nagai K, Yamagata K (2021) Preserved peritoneal function by short-term two-day peritoneal rest in hemodialysis combination therapy patients. J Artif Organs 24:296–300CrossRefPubMed Ueda A, Nagai K, Yamagata K (2021) Preserved peritoneal function by short-term two-day peritoneal rest in hemodialysis combination therapy patients. J Artif Organs 24:296–300CrossRefPubMed
18.
Zurück zum Zitat Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG (2001) Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transpl 16:2207–2213CrossRef Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG (2001) Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transpl 16:2207–2213CrossRef
19.
Zurück zum Zitat Wang AY-M, Wang M, Woo J, Lam CW-K, Lui S-F, Li PK-T, Sanderson JE (2004) Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15:2186–2194CrossRefPubMed Wang AY-M, Wang M, Woo J, Lam CW-K, Lui S-F, Li PK-T, Sanderson JE (2004) Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15:2186–2194CrossRefPubMed
20.
Zurück zum Zitat Rhee H, Yang JY, Jung WJ, Shin MJ, Yang BY, Song SH, Kwak IS, Seong EY (2014) Significance of residual renal function for phosphate control in chronic hemodialysis patients. Kidney Res Clin Pract 33:58–64CrossRefPubMedPubMedCentral Rhee H, Yang JY, Jung WJ, Shin MJ, Yang BY, Song SH, Kwak IS, Seong EY (2014) Significance of residual renal function for phosphate control in chronic hemodialysis patients. Kidney Res Clin Pract 33:58–64CrossRefPubMedPubMedCentral
Metadaten
Titel
Effects of incremental peritoneal dialysis with low glucose-degradation product neutral pH solution on clinical outcomes
verfasst von
Hasan Haci Yeter
Murat Altunok
Erdem Cankaya
Saliha Yildirim
Serkan Akturk
Serkan Bakirdogen
Hadim Akoğlu
Mesudiye Bulut
Tuncay Sahutoglu
Arda Erdut
Mehmet Ozkahya
Yener Koc
Onur Tunca
Ekrem Kara
Müge Erek
Mehmet Polat
Tulin Akagun
Galip Guz
Publikationsdatum
14.05.2024
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-024-04077-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.